8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
View Patent ↗8-Hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds are inhibitors of HIV integrase and inhibitors of HIV replication. More particularly, the compounds are of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The compounds are useful in the prevention and treatment of infection by ITV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are described.
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein
R 1 is —H, —C 1-6 alkyl, —C 3-6 cycloalkyl, or —C 1-6 alkyl which is substituted with 1 or 2 substituents each of which is independently:
(1) C 3-8 cycloalkyl,
(2) aryl,
(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;
wherein
(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, —C 1-6 alkyl, or —O—C 1-6 alkyl;
(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently
(1) —C 1-6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(2) —O—C 1-6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —S(O) n R c , —C(═O)N(R a R b ), —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 haloalkyl,
(5) —OH,
(6) halo,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a R b ),
(10) —C(═O)N(R a R b ),
(11) —C(═O)R a ,
(12) —CO 2 R c ,
(13) —SR c ,
(14) —S(═O)R c ,
(15) —SO 2 R c ,
(16) —N(R a )SO 2 R c ,
(17) —SO 2 N(R a R b ),
(18) —N(R a )C(═O)R b , or
(19) —N(R a )CO 2 R c ;
(C) each saturated or mono-unsaturated heterocyclic ring is
(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and
(D) each heteroaromatic ring or each fused bicyclic heterocycle is
(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl-aryl;
R 2 is —H or —C 1-6 alkyl;
R 3 is —H, —C 1-6 alkyl, —C 1-6 haloalkyl, or —C 1-6 alkyl substituted with one of —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b );
R 4 is:
(1) —H,
(2) —C 1-6 alkyl optionally substituted with one of —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )—C(R b )═O, —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), —N(R a )C(═O)N(R a R b ), —O—C 1-6 alkyl-C(═O)N(R a R b ), —S—C 1-6 alkyl-C(═O)N(R a R b ), —N(R a )—C 1-6 alkyl-C(═O)N(R a R b ), or —N(SO 2 R c )—C 1-6 alkyl-C(═O)N(R a R b ),
(3) —C 1-6 haloalkyl,
(4) —C(═O)R a ,
(5) —CO 2 R c ,
(6) —C(═O)N(R a R b ),
(7) —SO 2 N(R a R b ),
(8) —C 2-6 alkenyl,
(9) —C 2-6 alkenyl-C(═O)—N(R a ) 2 ,
(10) —C 2-5 alkynyl,
(11) —C 2-5 alkynyl-CH 2 N(R a ) 2 ,
(12) —C 2-5 alkynyl-CH 2 OR a ,
(13) —C 2-5 alkynyl-CH 2 S(O) n R c , or
(14) —R k ,
(15) —C 1-6 alkyl substituted with R k ,
(16) —C 1-6 haloalkyl substituted with R k ,
(17) —C 1-6 alkyl-O—R k ,
(18) —C 1-6 alkyl-O—C 1-6 alkyl-R k ,
(19) —C 1-6 alkyl-S(O) n —R k ,
(20) —C 1-6 alkyl-S(O) n —C 1-6 alkyl-R k ,
(21) —C 1-6 alkyl-N(R a )—R k ,
(22) —C 1-6 alkyl-N(R a )—C 1-6 alkyl-R k ,
(23) —C 1-6 alkyl-N(R a )—C 1-6 alkyl-OR k , with the proviso that the —N(R a )— moiety and the —OR k moiety are not both attached to the same carbon of the —C 1-6 alkyl-moiety,
(24) —C 1-6 alkyl-C(═O)—R k ,
(25) —C 1-6 alkyl-C(═O)N(R a )—R k ,
(26) —C 1-6 alkyl-N(R a )C(═O)—R k ,
(27) —C 1-6 alkyl-C(═O)N(R a )—C 1-6 alkyl-R k , or
(28) —C 1-6 alkyl-N(R a )—C 0-6 alkly-S(O) n R k ;
wherein R k is
(i) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently —C 1-6 alkyl, —C 1-6 alkyl-OH, —C 1-6 alkyl-O—C 1-6 alkyl, —C 1-6 alkyl-O—C 1-6 haloalkyl, —C 1-6 alkyl-N(R a R b ), —C 1-6 alkyl-C(═O)N(R a R b ), —C 1-6 alkyl-C(═O)R a , —C 1-6 alkyl-CO 2 R c , —C 1-6 alkyl-S(O) n R c , —O—C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 haloalkyl, —OH, halo, —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , or —SO 2 N(R a R b );
(ii) a 4- to 7-membered saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:
(a) optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
(b) optionally mono-substituted with aryl or HetA;
wherein HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and HetA is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; or
(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo;
R 5 is —H or —C 1-6 alkyl;
R 6 is:
(1) —O—C 1-6 alkyl,
(2) —N(R u R v ),
(3) —O—C 1-6 haloalkyl,
(4) —O—C 1-6 alkyl-aryl
(5) —O—C 1-6 alkyl-HetB, or
(6) —O—C 1-6 alkyl-HetC,
wherein
R u is —H or —C 1-6 alkyl;
R v independently has the same definition as R 1 ;
HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo;
each R a and R b is independently —H or —C 1-6 alkyl;
each R c is independently a —C 1-6 alkyl; and
each n is independently an integer equal to 0, 1 or 2.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 1 is —C 1-4 alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently
(1) —C 1-4 alkyl, optionally mono-substituted with —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —CN, —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(2) —O—C 1-4 alkyl, optionally mono-substituted with —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —S(O) n R c , —N(R a )—CO 2 R c , —C(═O)N(R a R b ), —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(3) —C 1-4 haloalkyl,
(4) —O—C 1-4 haloalkyl,
(5) —OH,
(6) halo,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a R b ),
(10) —SR c ,
(11) —S(═O)R c ,
(12) —SO 2 R c ,
(13) —N(R a )SO 2 R c ,
(14) —SO 2 N(R a R b ),
(15) —N(R a )C(═O)R b , or
(16) —N(R a )CO 2 R c ; and
R 6 is:
(1) —O—C 1-6 alkyl,
(2) —N(R u R v ),
(3) —O—C 1-6 haloalkyl,
(4) —O—C 1-6 alkyl-aryl
(5) —O—C 1-6 alkyl-HetB, or
(6) —O—C 1-6 alkyl-HetC,
wherein
R u is —H or —C 1-6 alkyl;
R v is —H, —C 1-6 alkyl, —C 3-6 cycloalkyl, or independently has the same definition as R 1 above;
HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo.
3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein in R 1 is —(CH 2 ) 1-4 -phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently
(1) —C 1-4 alkyl, optionally mono-substituted with —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —CN, —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , or —SO 2 N(R a R b ),
(2) —O—C 1-4 alkyl,
(3) —C 1-4 haloalkyl,
(4) —O—C 1-4 haloalkyl,
(5) —OH,
(6) halo,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a R b ),
(10) —SR c ,
(11) —S(═O)R c ,
(12) —SO 2 R c ,
(13) —N(R a )SO 2 R c ,
(14) —SO 2 N(R a R b ),
(15) —N(R a )C(═O)R b , or
(16) —N(R a )CO 2 R c .
4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 1 is:
wherein X 1 and X 2 are each independently
(1) —H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) —CF 3 ,
(7) fluoro,
(8) bromo, or
(9) chloro.
5. The compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is 4-fluorobenzyl.
6. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
R 2 is —H or —C 1-4 alkyl;
R 3 is —H or —C 1-4 alkyl;
R 4 is:
(1) —H,
(2) —C 1-4 alkyl optionally substituted with one of —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —CN, —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )—C(R b )═O, —N(R a )SO 2 R b , or —N(R a )SO 2 N(R a R b ),
(3) —C(═O)N(R a R b ),
(4) —R k ,
(5) —C 1-4 alkyl substituted with R k ,
(6) —C 1-4 alkyl-O—R k , or
(7) —C 1-4 alkyl-O—C 1-4 alkyl-R k ; and
R 5 is —H.
7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is:
(1) —O—C 1-4 alkyl,
(2) —N(R u R v ),
(3) —O—C 1-4 haloalkyl,
(4) —O—C 1-4 alkyl-aryl
(5) —O—C 1-4 alkyl-HetB, or
(6) —O—C 1-4 alkyl-HetC,
wherein
R u is —H or —C 1-4 alkyl;
R v is —H, —C 1-4 alkyl, or cyclopropyl;
HetB is a 5- or 6-membered saturated ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the saturated ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, —C 1-4 alkyl, —C 1-4 haloalkyl, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, or oxo; and
HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently —C 1-4 alkyl, —C 1-4 haloalkyl, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, or oxo.
8. A compound of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein:
X 1′ and X 2′ are each independently:
(1) —H,
(2) C 1-4 alkyl,
(2) —O—C 1-4 alkyl,
(3) —C 1-4 haloalkyl,
(4) —O—C 1-4 haloalkyl, or
(5) halo; and
R 6′ is:
(1) —O—C 1-4 alkyl, or
(2) —N(R u R v );
wherein
R u is —H or —C 1-4 alkyl; and
R v is —C 1-4 alkyl or cyclopropyl.
9. A compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein:
wherein X 1′ and X 2′ are each independently:
(1) —H,
(2) methyl,
(2) —OCH 3 ,
(3) —CF 3 ,
(4) —OCF 3 ,
(5) chloro,
(6) fluoro, or
(7) bromo; and
R 6′ is:
(1) methoxy
(2) ethoxy, or
(3) —N(R u R v );
wherein
R u is —H; and
R v is methyl, ethyl, or cyclopropyl.
10. The compound according to claim 8 , which is a compound of Formula (III), or a pharmaceutically acceptable salt thereof:
wherein X 1′ and X 2′ are each independently —H or halo.
11. The compound according to claim 10 , or a pharmaceutically acceptable salt thereof, wherein
X 1′ and X 2′ are each independently —H, fluoro, chloro, or bromo; and
R 6′ is:
(1) methoxy,
(2) ethoxy, or
(3) —N(R u R v );
wherein
R u is —H; and
R v is methyl, ethyl, or cyclopropyl.
12. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of Formula (IV):
wherein
R u is —H or —C 1-6 alkyl;
R v is C 1-6 alkyl which is substituted with 1 or 2 substituents each of which is independently:
(1) C 3-8 cycloalkyl,
(2) aryl,
(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;
wherein
(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, —C 1-6 alkyl, or —O—C 1-6 alkyl;
(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently
(1) —C 1-6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —CN, —NO 2 , —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , S(O) n R c , —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(2) —O—C 1-6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently —OH, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, —S(O) n R c , —C(═O)N(R a R b ), —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(3) —C 1-6 haloalkyl,
(4) —O—C 1-6 haloalkyl,
(5) —OH,
(6) halo,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a R b ),
(10) —C(═O)N(R a R b ),
(11) —C(═O)R a ,
(12) —CO 2 R c ,
(13) —SR c ,
(14) —S(═O)R c ,
(15) —SO 2 R c ,
(16) —N(R a )SO 2 R c ,
(17) —SO 2 N(R a R b ),
(18) —N(R a )C(═O)R b , or
(19) —N(R a )CO 2 R c ;
(C) each saturated or mono-unsaturated heterocyclic ring is
(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and
(D) each heteroaromatic ring or each fused bicyclic heterocycle is
(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, —C 1-6 alkyl, —C 1-6 haloalkyl, —O—C 1-6 alkyl, —O—C 1-6 haloalkyl, or oxo; and
(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or —C 1-6 alkyl-aryl; and
R 1 is —H or —C 1-6 alkyl.
13. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein R v is —C 1-4 alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently
(1) —C 1-4 alkyl, optionally mono-substituted with —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —CN, —N(R a R b ), —C(═O)N(R a R b ), —C(═O)R a , —CO 2 R c , —S(O) n R c , —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(2) —O—C 1-4 alkyl, optionally mono-substituted with —OH, —O—C 1-4 alkyl, —O—C 1-4 haloalkyl, —S(O) n R c , —N(R a )—CO 2 R c , —C(═O)N(R a R b ), —SO 2 N(R a R b ), —N(R a )C(═O)R b , —N(R a )CO 2 R c , —N(R a )SO 2 R c , —N(R a )SO 2 N(R a R b ), —OC(═O)N(R a R b ), or —N(R a )C(═O)N(R a R b ),
(3) —C 1-4 haloalkyl,
(4) —O—C 1-4 haloalkyl,
(5) —OH,
(6) halo,
(7) —CN,
(8) —NO 2 ,
(9) —N(R a R b ),
(10) —SR c ,
(11) —S(═O)R c ,
(12) —SO 2 R c ,
(13) —N(R a )SO 2 R c ,
(14) —SO 2 N(R a R b ),
(15) —N(R a )C(═O)R b , or
(16) —N(R a )CO 2 R c .
14. The compound according to claim 13 , or a pharmaceutically acceptable salt thereof, wherein R v is:
wherein X 1 and X 2 are each independently
(1) —H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) —CF 3 ,
(7) fluoro,
(8) bromo, or
(9) chloro.
15. The compound according to claim 14 , or a pharmaceutically acceptable salt thereof, wherein R v is 4-fluorobenzyl.
16. The compound according to claim 12 , or a pharmaceutically acceptable salt thereof, wherein:
R u is —H;
R 5 is —H;
R 4 is:
(1) —H,
(2) —C 1-4 alkyl optionally substituted with one of —OH, —N(R a R b ), or —C(═O)N(R a R b ),
(3) —C(═O)N(R a R b ),
(4) —(CH 2 ) 1-3 —R k ,
(5) —(CH 2 ) 1-3 —O—R k , or
(6) —(CH 2 ) 1-3 —O—(CH 2 ) 1-3 —R k ;
R 2 is —H; and
R 1 is —C 1-4 alkyl.
17. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. A method for treating infection by HIV-1 or for treating or delaying the onset of AIDS due to HIV-1 in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.